Chemical industry in Austria

Projects in Austria

chemXplore tracks 20 projects in Austria, of which 8 are active.

3 Announced / Concept 1 FEED / Pre-FID 3 Under Construction 1 Commissioning & Start-up

5 new construction and 3 expansion.

Expected to start operating
2026
none
2027
1 project
2028
1 project
2029
none
2030
none
2031
none

3 of the active projects carry no start-up date yet.

What moved recently
  • August 2026 ANDRITZ Linz Turbogenerator Expansion · Commissioning & Start-up
  • 8 July 2026 RAG Austria Gampern electrolyser expansion to 15 MW · Under Construction
  • 1 July 2026 OMV Tiefenkraft Deep Geothermal Project, Styria · Announced / Concept

Owners and developers: Evonik Industries AG (2), OMV Aktiengesellschaft (2), RAG Austria AG (2), ANDRITZ GROUP (1), Energie Steiermark AG (1), Graforce GmbH (1)

Investors: Abu Dhabi Future Energy Company PJSC – Masdar (1), Austria Wirtschaftsservice GmbH (1), European Investment Bank (1), RAG Austria AG (1), TerraVolta Resources (1)

Contractors, licensors, and offtakers are recorded on 3 of these 8 projects For subscribers

Targeting: Hydrogen (3), Carbon (1), Carbon dioxide (1), Methane (1), Water (1)

Follow these projects in chemXplore →

Latest Austrian chemical industry news

1 October 2026
Roche: VOYAGER real‑world data confirm Vabysmo effectiveness and safety in nAMD, DME and RVO

VOYAGER shows Vabysmo yields vision gains, marked CST reductions and reduced retinal fluid across nAMD, DME and RVO in routine practice, with no new safety signals.

30 September 2026
Lilly’s Foundayo shows cardiovascular safety and durable A1C and weight benefits in ACHIEVE‑4

Once‑daily oral GLP‑1 cut MACE vs insulin glargine, lowered A1C by 1.6% at 52 weeks and produced mean weight loss of 8.1 kg with durable effects to 104 weeks.

30 September 2026
Genentech: VOYAGER shows Vabysmo effective and safe across wet AMD, DME and RVO

VOYAGER real-world data show Vabysmo improves vision and reduces retinal thickness across wet AMD, DME and RVO, with rapid anatomical drying and no new safety signals.

30 September 2026
Lilly: Lebrikizumab (EBGLYSS) meets primary endpoint in Phase 3b ADtouch for hand and foot atopic dermatitis

Rapid, significant relief in skin clearance, itch, pain and patient satisfaction versus placebo; consistent safety and fewer patients required rescue medication.

24 September 2026
European Commission T&Cs for €1bn industrial heat decarbonisation auction

€1bn Europe-wide auction for industrial process-heat decarbonisation; bidding opens early Dec 2026. Supports electrification, renewable heat and SMRs with a fixed premium per tCO2.

18 September 2026
EMA: benefits of sodium oxybate still outweigh risks in alcohol dependence

CHMP found methodological limits in existing efficacy studies and asked companies to run new post‑authorisation trials; medicines remain available in Austria and Italy and no new safety concerns were found.

18 September 2026
EMA CHMP restricts and redefines ipidacrine indications

CHMP limits ipidacrine to specific neuropathies, Alzheimer’s, intestinal atony and certain stroke/TBI recovery uses; removes several neuritis and demyelinating indications; cautions >80 mg/day.

17 September 2026
EASA: EU SAF supply surpasses 2025 ReFuelEU target

SAF reached 1.1 Mt (2.8% share), a near sixfold rise from 2024; supplied at 121 airports, 84% produced in the EU, and 18 Member States host production projects.

27 August 2026
ANDRITZ doubles turbogenerator production capacity at Linz plant

700 m² hall added; site now assembles hydrogen-cooled units and can ship generators up to 300 t via the Danube; further 3,000 m² refit due 2028.

27 August 2026
Agilyx ASA completes strategic reset and consolidates GreenDot

GreenDot consolidated from 20 April; Group revenue €85.1m, EBITDA -€1.9m and net profit €9.7m driven by €30.2m non‑cash gains; GreenDot H1 revenue €229m.

Chemical parks and clusters

active / all projects